Sign in

Private company

Assertio Holdings, Inc.

In its 2026 annual report the company says: “We are a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology market. We have built our product portfolio through the acquisition or licensing of approved products, including our lead product, ROLVEDON, which we acquired on July 31, 2023, through a merger with Spectrum.”4 It is headquartered in Lake Forest, Illinois.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersLake Forest, Illinois1
  • Incorporated inDE2
  • Business address100 S. Saunders Road, Suite 300, Lake Forest, Il 600452
  • Filer categoryAccelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. Our focus is on supporting patients by marketing products primarily in the oncology market.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-18.1%Operating margin5
-25.6%Net margin5
-5.0%Revenue growth, 20255
-32.3%Return on equity5
0.42×Debt to equity5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development1¢$1.7M
  • Selling, general and admin58¢$69.0M
  • Other costs40¢$47.6M
  • Income tax0¢$435.0K

Out of $118.7M in revenue.5 The company lost money this year.

Financial statements

Revenue6789105$118.7M in 2025−48% since 2019
0$100.0M$200.0M$300.0M2019: $229.5M$229.5M20192020: $106.3M$106.3M2020−54%2021: $111.0M$111.0M2021+4%2022: $156.2M$156.2M2022+41%2023: $152.1M$152.1M2023−3%2024: $125.0M$125.0M2024−18%2025: $118.7M$118.7M2025−5%
Operating income6789105-$21.5M in 2025−89% since 2019
-$300.0M-$200.0M-$100.0M0$100.0M2019: -$194.4M-$194.4M20192020: -$82.2M-$82.2M2020−58%2021: $9.4M$9.4M20212022: $39.4M$39.4M2022+318%2023: -$243.5M-$243.5M20232024: -$24.5M-$24.5M2024−90%2025: -$21.5M-$21.5M2025−12%
Net income6789105-$30.4M in 2025−86% since 2019
-$400.0M-$200.0M0$200.0M2019: -$217.2M-$217.2M20192020: -$28.1M-$28.1M2020−87%2021: -$1.3M-$1.3M2021−95%2022: $109.6M$109.6M20222023: -$331.9M-$331.9M20232024: -$21.6M-$21.6M2024−93%2025: -$30.4M-$30.4M2025+41%
Fiscal year2019202020212022202320242025
Revenue$229.5M6$106.3M7$111.0M8$156.2M9$152.1M10$125.0M5$118.7M5
Cost of revenue$9.5M6$19.9M7$15.8M7
Research and development$09$2.8M10$3.8M5$1.7M5
Selling, general and admin$108.9M6$104.3M7$52.6M8$46.8M9$78.6M10$75.1M5$69.0M5
Operating expenses$101.6M8$116.8M9$395.6M10$149.4M5$140.2M5
Operating income-$194.4M6-$82.2M7$9.4M8$39.4M9-$243.5M10-$24.5M5-$21.5M5
Interest$58.4M6$15.9M7$10.2M8$8.0M8
Income before tax-$553.0K8$31.2M9-$254.1M10-$21.5M5-$29.9M5
Income tax-$5.3M6-$17.4M7$728.0K8-$78.5M9$77.9M10$52.0K5$435.0K5
Net income-$217.2M6-$28.1M7-$1.3M8$109.6M9-$331.9M10-$21.6M5-$30.4M5
Earnings per share-$3.076-$1.077-$0.038$2.339-$4.6710-$3.405-$4.745
Earnings per share (diluted)-$3.076-$1.077-$0.038$2.039-$4.6710-$3.405-$4.745
Shares (weighted, basic)43.2M shares847.0M shares971.0M shares106.4M shares56.4M shares5
Shares (weighted, diluted)43.2M shares854.7M shares971.0M shares106.4M shares56.4M shares5

Compare Assertio Holdings, Inc. with another company

Corporate structure

Assertio Holdings, Inc. sits at the top of its group. 14 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Assertio Holdings, Inc.

  • Assertio Holdings, Inc. Lake Forest, Illinois
    • Alligator IP, LLC Subsidiary · Delaware, United States
    • Allos Therapeutics, Inc. Subsidiary · Delaware, United States
    • ASIO Holdings, LLC Subsidiary · Texas, United States
    • Assertio Distribution, LLC Subsidiary · Delaware, United States
    • Assertio Management, LLC Subsidiary · Delaware, United States
    • Assertio Specialty Pharmaceuticals, LLC Subsidiary · Delaware, United States
    • Depo DR Sub, LLC Subsidiary · Delaware, United States
    • Spectrum Oncology Private Limited Subsidiary · India
    • Spectrum Pharmaceuticals International Holdings, LLC Subsidiary · Delaware, United States
    • Spectrum Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Talon Therapeutics, Inc. Subsidiary · Delaware, United States
    • Zyla Life Sciences US, LLC Subsidiary · Delaware, United States
    • Zyla Life Sciences, LLC Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Assertio Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.0M5 Dec 31, 2025$4.0M5 Dec 31, 20240%
Accumulated depreciation$3.5M5 Dec 31, 2025$3.4M5 Dec 31, 2024+4.2%
Property and equipment, net$444.0K5 Dec 31, 2025$586.0K5 Dec 31, 2024−24.2%
Operating-lease assets (leased space)$971.0K5 Dec 31, 2025$1.1M5 Dec 31, 2024−13.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$10.2M5 Dec 31, 2025$50.6M5 Dec 31, 2024−79.8%
Marketable securities, current$53.2M5 Dec 31, 2025$49.5M5 Dec 31, 2024+7.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$48.9M5 Dec 31, 2025$80.5M5 Dec 31, 2024−39.2%
Finite-lived intangibles, gross$176.2M5 Dec 31, 2025$192.6M5 Dec 31, 2024−8.5%
Accumulated amortization$125.6M5 Dec 31, 2025$106.9M5 Dec 31, 2024+17.5%
Finite-lived intangibles, net$48.9M5 Dec 31, 2025$80.5M5 Dec 31, 2024−39.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$24.1M5 Dec 31, 2025$38.3M5 Dec 31, 2024−37.0%
Raw materials$15.2M5 Dec 31, 2025$15.5M5 Dec 31, 2024−2.3%
Work in process$6.1M5 Dec 31, 2025$4.9M5 Dec 31, 2024+23.5%
Finished goods$2.9M5 Dec 31, 2025$17.9M5 Dec 31, 2024−83.8%

Properties, in its own words

Our corporate headquarters is located in Lake Forest, Illinois, where we lease approximately 20,000 square feet of office space through December 31, 2030. Our facility is used for office purposes only and no commercial manufacturing takes place at our facility. For additional information, see “Item 8. Financial Statements and Supplementary Data - Note 7. Leases.”

Additionally, in connection with the Spectrum Merger, we assumed leases for two facilities (whose terms ended in the third quarter of 2025) and certain office equipment (which term ends in September 2026) for which Spectrum had previously been the lessee. For additional information regarding these leases, see “Item 8. Financial Statements and Supplementary Data - Note 16. Restructuring Charges.”

Item 2 of the 10-K filed Mar 16, 2026.4

Leadership

Who has led Assertio Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel A. Peisert2021–2023
  2. Heather L. Mason2024
  3. Brendan P. O'Grady2024–2025
  4. Mark L. Reisenauer2025–now

President

  1. Daniel A. Peisert2021–2023
  2. Paul Schwichtenberg2026–now

Chief financial officer

  1. Daniel A. Peisert2020
  2. Paul Schwichtenberg2021–2023
  3. Ajay Patel2024–now

Chief operating officer

  1. Mark Strobeck2020
  2. Paul Schwichtenberg2026–now
2025
Board members and other officers (20)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • ASIO Holdings, LLC Texas3
  • Alligator IP, LLC Delaware3
  • Allos Therapeutics, Inc. Delaware3
  • Assertio Distribution, LLC Delaware3
  • Assertio Management, LLC Delaware3
  • Assertio Specialty Pharmaceuticals, LLC Delaware3
  • Depo DR Sub, LLC Delaware3
  • Spectrum Oncology Private Limited India3
  • Spectrum Pharmaceuticals International Holdings, LLC Delaware3
  • Spectrum Pharmaceuticals, Inc. Delaware3
  • Talon Therapeutics, Inc. Delaware3
  • Zyla Life Sciences US, LLC Delaware3
  • Zyla Life Sciences, LLC Delaware3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Assertio Therapeutics, IncAug 15, 2018 to May 10, 20192
  • DEPOMED INCJun 21, 2004 to May 26, 20162

Timeline

  1. Jun 16, 20268-K Entered a material agreement; Completed an acquisition or sale; Debt or obligation accelerated41
  2. May 18, 20268-K Other events42
  3. May 13, 20268-K Entered a material agreement; Ended a material agreement; Regulation FD disclosure43
  4. May 8, 20268-K Regulation FD disclosure44
  5. May 7, 20268-K Executive or director change; Shareholder vote45
  6. May 5, 20268-K Regulation FD disclosure46
  7. May 4, 20268-K Entered a material agreement; Regulation FD disclosure47
  8. Apr 29, 20268-K Regulation FD disclosure48
  9. Apr 21, 20268-K Regulation FD disclosure49
  10. Apr 14, 20268-K Completed an acquisition or sale50
  11. Apr 9, 20268-K Entered a material agreement; Executive or director change; Regulation FD disclosure51
  12. Apr 9, 20268-K Entered a material agreement; Executive or director change; Regulation FD disclosure52
  13. Nov 14, 2025New chief executive Mark L. Reisenauer becomes CEO14
  14. Jun 4, 2024New chief executive Brendan P. O'Grady becomes CEO16
  15. Jan 4, 2024New chief executive Heather L. Mason becomes CEO15
  16. Feb 8, 2021New chief executive Daniel A. Peisert becomes CEO17

Calendar

When it reported results

  1. Mar 16, 2026Reported quarterly or annual results53
  2. Nov 10, 2025Reported quarterly or annual results54
  3. Aug 11, 2025Reported quarterly or annual results55
  4. May 12, 2025Reported quarterly or annual results56
  5. Mar 12, 2025Reported quarterly or annual results57
  6. Nov 12, 2024Reported quarterly or annual results58
  7. Aug 7, 2024Reported quarterly or annual results59
  8. May 6, 2024Reported quarterly or annual results60

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

331 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 62 major events, 142 insider forms, 16 large holders, 92 other. The latest 20:

  1. Jul 31, 202615-12G EDGAR
  2. Jun 26, 202615-12G EDGAR
  3. Jun 17, 2026EFFECT EDGAR
  4. Jun 17, 2026EFFECT EDGAR
  5. Jun 17, 2026EFFECT EDGAR
  6. Jun 17, 2026EFFECT EDGAR
  7. Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
  8. Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
  9. Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
  10. Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
  14. Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
  15. Jun 16, 20264 OWNERSHIP DOCUMENT EDGAR
  16. Jun 16, 2026S-8 POS EDGAR
  17. Jun 16, 2026S-8 POS EDGAR
  18. Jun 16, 2026S-8 POS EDGAR
  19. Jun 16, 2026S-8 POS EDGAR
  20. Jun 16, 2026S-8 POS EDGAR

The 331 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 4 buys and 14 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 10, 2025Stark David MatthewDirectorSale8,959$0.76$6.8KForm 4
Nov 18, 2024Mason Heather LDirectorBuy75,000$0.80$60.0KForm 4
Nov 14, 2024O'Grady Brendan P.CEOBuy11,706$0.85$9.9KForm 4
Jun 11, 2024Vacirca Jeff LDirectorBuy10,000$1.11$11.1KForm 4
Jun 5, 2024Mason Heather LDirectorBuy25,000$0.97$24.2KForm 4
Mar 14, 2024Tyree James LDirectorSale10,251$1.12$11.5KForm 4
Sep 12, 2023Peisert Daniel A.President & CEOSale31,121$2.97$92.4KForm 4
Sep 11, 2023Schlessinger SamEVP, General CounselSale45,236$3.04$137.5KForm 4
Sep 11, 2023Patel AjayEVP and CFOSale64,313$3.04$195.5KForm 4
Sep 11, 2023Schwichtenberg PaulPresident and COOSale104,980$3.07$322.3KForm 4
Sep 11, 2023Peisert Daniel A.President & CEOSale127,281$3.04$386.9KForm 4
Aug 14, 2023MCKEE WILLIAMDirectorSale22,000$3.14$69.1KForm 4
May 19, 2023Mason Heather LDirectorSale89,286$7.30$651.8KForm 4
May 5, 2023Tyree James LDirectorSale43,143$6.00$258.9KForm 4
May 12, 2022Tyree James LDirectorSale44,643$2.36$105.4KForm 4
May 12, 2022MCKEE WILLIAMDirectorSale22,322$2.35$52.5KForm 4
Apr 11, 2022Peisert Daniel A.President & CEOSale26,391$3.50$92.4KForm 4
Apr 5, 2022Peisert Daniel A.President & CEOSale34,518$3.50$120.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Brendan P. O’Grady$721.9K$1.9M69
2025Mark L. Reisenauer61$202.1K$1.4M69
2025Paul Schwichtenberg55$463.2K$945.6K69
2025Ajay Patel42$461.1K$921.2K69
2024Former President and Chief Executive Officer$502.4K$3.0M69
2024Executive Vice PresidentChief Financial Officer$445.4K$952.7K69
2024PresidentChief Operating Officer$430.0K$932.4K69

SEC filer profile

How Assertio Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAssertio Holdings, Inc.1
  • CIK0001808665
  • Employer ID (EIN)85-05983784
  • Filer statusAccelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address100 S. Saunders Road, Suite 300, Lake Forest, IL 600451
  • Phone(224) 419-71061
  • Shares outstanding6,462,180 as of May 6, 202613
  • Public float$60.7M as of Jun 30, 20254
  • AuditorGRANT THORNTON LLP, Chicago, Illinois PCAOB ID 248; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceJun 21, 20041
  • Filings464 in all: 4 (167), 8-K (79), S-8 POS (37), 10-Q (18), S-8 (17), 3 (16), SC 13G/A (14), SC14D9C (11)1
    All 40 form types

    144 (10), EFFECT (8), SC 13G (7), 10-K (6), DEF 14A (6), SC TO-C (6), UPLOAD (6), 8-K/A (5), CORRESP (5), 425 (4), ARS (4), POS AM (4), PRE 14A (4), PX14A6G (3), SCHEDULE 13G/A (3), 15-12G (2), 424B3 (2), 424B5 (2), DEFA14A (2), S-3 (2), S-4 (2), S-4/A (2), 25-NSE (1), 5 (1), 8-K12B (1), CT ORDER (1), DEFR14A (1), SC 13D (1), SC 14D9 (1), SC 14D9/A (1), SC TO-T (1), SC TO-T/A (1)

  • Latest filingsAnnual report (10-K) Mar 16, 2026
    Quarterly report (10-Q) May 8, 2026
    Proxy statement (DEF 14A) Apr 6, 2026
    Latest 8-K (8-K) Jun 16, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par valueASRTThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 16, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Assertio Holdings, Inc. names in Item 1A of its 10-K filed Mar 16, 2026: 40 risks under these headings, as written.4

  • Risks Related to Commercial Matters
  • Sales of ROLVEDON depend on coverage and reimbursement from third-party payors, including under the Medicare Part B Average Sales Price (“ASP”) payment methodology, and a failure to obtain or a reduction in the coverage and/or reimbursement for our products, including as a result of disputes with government agencies regarding our submitted ASP data for ROLVEDON, which is subject to assumptions that may be challenged, could have a material adverse impact on our product sales, business and results of operations.
  • If we are not successful in driving the growth in sales and profitability of ROLVEDON, our business, financial condition and results of operations will be materially and adversely affected.
  • If we are not successful in commercializing our products, our business, financial condition and results of operations will be materially and adversely affected.
  • We depend on one qualified supplier for the API in each of our products, and we depend on third parties that are single source suppliers to manufacture our products. Insufficient availability of our products, the API or other raw materials necessary to manufacture our products, or the inability of our suppliers to manufacture and supply our products on commercially reasonable terms, will adversely impact our sales and/or margins upon depletion of our API and product inventories.
  • A number of our products, including the INDOCIN products and Cambia, are facing competition from generics, which adversely affects our business. Approval of additional generic or biosimilar versions of our products would have a further adverse effect on our business.
  • Our commercialization, collaborative and/or licensing arrangements may give rise to disputes over commercial terms, contract interpretation and ownership or protection of our intellectual property and may adversely affect the commercial success of our products.
  • We and our commercial partners may be unable to compete successfully in the pharmaceutical and biological product industry.
  • If we are unable to negotiate acceptable pricing or obtain adequate reimbursement for our products from third-party payors, our business will suffer.
  • Our customer concentration can materially adversely affect our financial condition and results of operations.
  • Risks Related to Our Regulatory Environment
  • We are subject to risks from changes in laws and regulations applicable to, and increased scrutiny and investigations of, the pharmaceutical industry, which can adversely affect our business, financial condition and results of operations.
The other 30 risks
  • Our products, including the marketing of our products, is subject to substantial regulation in the U.S. and any failure by us or our commercial and collaborative partners to comply with applicable statutes or regulations can adversely affect our business.
  • We may incur significant liability if it is determined that we are promoting or have in the past promoted the “off-label” use of our products.
  • Healthcare reform can reduce our revenues, increase our expenses and adversely affect the commercial success of our products.
  • We are not always able to protect our intellectual property and are subject to risks from liability for infringing the intellectual property of others.
  • Macroeconomic conditions can materially impact our business and operations.
  • Risks Related to Our Business Development Activities
  • Our success is dependent on our ability to successfully execute business development strategies, strategic partnerships, acquisitions of businesses, product candidates, products, or technologies, and investment opportunities to build and grow for the future. Our failure or inability to do so will limit our business growth and prospects.
  • Strategic transactions that fail to achieve the anticipated levels of revenue, synergies and profit growth will cause our business to suffer.
  • Failure to integrate any business, product or technology we acquire, will cause our business, financial condition and operating results to suffer.
  • Risks Related to Our Financial Position
  • Our existing capital resources may not be sufficient to fund our future operations or product acquisitions and strategic transactions that we may pursue.
  • Our failure to generate sufficient cash flow from our business to make payments on our debt would adversely affect our business, financial condition and results of operations. Our indebtedness could limit our ability to incur additional debt to fund our operations.
  • We have incurred operating losses in the past and may incur operating losses in the future.
  • We have significant amounts of long-lived assets which depend upon future positive cash flows to support the value recorded in our balance sheet. We have recognized impairment charges in the past and may recognize impairment charges in the future should actual financial results differ materially from our projections.
  • We have significant amounts of inventory, and we have recognized inventory write-off charges in the past and may recognize write-off charges in the future.
  • Our financial results are impacted by management’s assumptions and use of estimates.
  • We face risks relating to product liability losses and other litigation liability for which we may be unable to maintain or obtain adequate insurance.
  • Our ability to use NOLs to offset future taxable income may be limited.
  • Risks Related to Future Product Development
  • The development of drug and biological product candidates is inherently difficult and uncertain, and we cannot be certain that any of our future product candidates will be approved for marketing or, if approved, will achieve market acceptance. Failure to obtain regulatory approval for our products, our raw materials or future product candidates, will limit our ability to commercialize our products, and our business will suffer.
  • We and our collaborative partners customarily depend on third-party contract research organizations, clinical investigators and clinical sites to conduct clinical trials with regard to product candidates, and if they do not perform their regulatory, legal and contractual obligations, or successfully enroll patients in and manage our clinical trials, we and our collaborative partners may not be able to obtain regulatory approvals for future product candidates.
  • We are subject to risks associated with NDAs we submit under Section 505(b)(2) of the FDCA.
  • Risks Related to Share Ownership
  • Our common stock may be delisted from The Nasdaq Capital Market if we are unable to maintain compliance with its continued listing standards.
  • The market price of our common stock historically has been volatile. Our results of operations have and may continue to fluctuate and affect our stock price.
  • Our business could be impacted as a result of actions by activist shareholders, including as a result of a potential proxy contest for the election of directors at future annual meetings.
  • We are subject to risks related to unsolicited takeover attempts in the future.
  • Conversions of the 2027 Convertible Notes or future sales of our common stock or equity-linked securities in the public market could lower the market price of our common stock and adversely impact the trading price of the 2027 Convertible Notes.
  • Risks Related to our Corporate Organization and General Business Risks
  • Our success is dependent in large part upon the continued services of our executive management team.
  • Despite our corporate structure, creditors of our current or former operating subsidiaries could be successful in piercing the corporate veil otherwise reaching the assets of one another, which could have an adverse effect on us and our operating results, results from continued operations, and financial condition.
  • If we are unable to satisfy regulatory requirements relating to internal controls, our stock price could suffer.
  • Business interruptions due to natural disasters and other emergencies could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.
  • Data breaches and cyber-attacks or other failures in our telecommunications or information technology systems, or those of our third-party vendors or other contractors or consultants, could result in information theft, data corruption and significant disruption of our business operations.
  • The use of new and evolving technologies, such as AI and ML, in our operations, and the operations of third parties upon which we rely, may result in spending additional resources and present new risks and challenges that can impact our business including by posing security and other risks to our sensitive data, and as a result we may be exposed to reputational harm, other adverse consequences, and liability.

Legal proceedings

For a description of our material pending legal proceedings, see “Item 8. Financial Statements and Supplementary Data - Note 8. Commitments and Contingencies.”

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69